Maxsulid

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Maxsulid

Property Description
Active ingredient Nimesulide
Form Granules for oral suspension, Dispersible tablets
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
Common use Symptomatic relief of acute pain, inflammation, and fever
Origin Synthetic molecule (Sulfonanilide derivative)

Maxsulid is a pharmaceutical preparation containing the active ingredient Nimesulide, primarily used for its analgesic (pain-relieving) and anti-inflammatory properties. It is chemically defined as a sulfonanilide derivative, a synthetic molecule that belongs to a specific chemical subgroup within its broader class, identified by its chemical formula, C13H12N2O5S. Maxsulid is generally classified as a prescription-only medicine.


Maxsulid: Defining the Pharmacological Class

Maxsulid's active substance, Nimesulide, is firmly classified within the Nonsteroidal Anti-Inflammatory Drug (NSAID) pharmacological class. This means its core function is to modulate the body's inflammatory response, which is a key driver of both pain and swelling. Nimesulide is specifically recognized as a preferential cyclooxygenase-2 (COX-2) inhibitor. This mechanism has been clinically recognized for its efficacy in managing acute pain, focusing its action on the processes that cause inflammation.


Composition and Available Forms

Maxsulid is a single-ingredient product where Nimesulide is the sole active substance. The product is designed for oral administration, making it a systemic treatment. Commonly, Maxsulid is supplied as granules for oral suspension or dispersible tablets, pharmaceutical forms that require preparation or dissolution prior to swallowing. This offers an accessible method of delivery, which can be particularly relevant for patient groups who may have difficulty swallowing conventional capsules. The NSAID class functions by interfering with the body's natural production of prostaglandins.


General Therapeutic Purpose and Action Type

The general therapeutic purpose of Maxsulid is to provide symptomatic treatment by mitigating the physical manifestations of inflammation and discomfort. It is used to achieve three key actions: analgesic (pain relief), anti-inflammatory (reduction of swelling), and antipyretic (fever reduction). These actions stem from the drug's mechanism as a COX-2 preferential inhibitor, which helps to limit the production of prostaglandins—the compounds that trigger pain and fever signals. For example, the drug is commonly used for the general relief of short-term pain symptoms often associated with conditions like primary dysmenorrhea.

Regulatory References

  1. Nimesulide - referral | European Medicines Agency
  2. U.S. National Library of Medicine

What side effects are possible with Maxsulid?

Maxsulid: Possible Side Effects and Safety Information

Maxsulid, which contains the active substance Nimesulide, is associated with a risk of serious adverse reactions, primarily affecting the liver. Due to this safety concern, its use is subject to strict limitations and should only be considered as a second-line treatment when other non-steroidal anti-inflammatory drugs (NSAIDs) have not been effective.

Serious and Clinically Significant Risks

The most serious documented safety concern is hepatotoxicity, which is damage to the liver. This risk is increased with longer exposure and is the primary reason why treatment duration is officially restricted to a maximum of 15 days. Reports have included cases of acute liver failure, sometimes requiring liver transplantation, even following short-term use. Potential signs of liver problems may include persistent fatigue, dark urine, loss of appetite, and yellowing of the skin or eyes.

Like other NSAIDs, Maxsulid also carries a risk of adverse effects on the gastrointestinal system, such as nausea, diarrhea, vomiting, and in rare cases, gastrointestinal bleeding or peptic ulcers.

Safety Restrictions and Contraindications

To minimize risks, regulatory bodies impose the following safety restrictions and mandatory contraindications:

  • Maximum Duration: Treatment must not exceed 15 consecutive days.
  • Maximum Dose: The maximum dose is restricted to 100 mg twice daily.
  • Contraindications: Maxsulid must not be used in patients with existing liver problems, active gastrointestinal bleeding or ulcers, or severe heart or kidney failure.
  • Drug Interactions: It is contra-indicated for use with other medicines known to cause liver damage (hepatotoxic drugs).
  • Population: It is not recommended for use in children under 12 years of age or during the third trimester of pregnancy.

Patients should be fully aware of the potential for liver-related side effects, and therapy must be immediately discontinued if signs of liver injury develop.

Overdose and Emergency Response

Maxsulid (Nimesulide) Overdose requires immediate emergency attention due to the potential for serious and life-threatening systemic outcomes documented in official government regulatory labeling.

Manifestations and Severe Outcomes Official Regulatory Statement
Documented Presentations Acute overdose may be characterized by general signs of distress including lethargy, drowsiness, nausea, vomiting, and localized epigastric pain (upper abdominal discomfort).
Life-Threatening Risks Severe complications documented in regulatory sources include gastrointestinal bleeding, hypertension, acute renal failure, respiratory depression, and, in rare instances, coma.

Emergency Action and Management Mandate

The official regulatory position is that individuals must seek immediate medical attention for any suspected overdose. The presence of risks such as acute renal failure or central nervous system depression leading to coma dictates that urgent hospital treatment may be required for life support.

As no specific antidote is available for Maxsulid overdose, management is entirely limited to providing symptomatic and supportive care. This regulatory constraint ensures treatment focuses on mitigating the documented severe outcomes and supporting vital physiological functions.

Therapeutic Uses of Maxsulid

What Maxsulid Treats: Main Uses and Benefits

Maxsulid is applied across domains where additional symptomatic support is needed for conditions marked by heightened symptom expression. The drug is commonly used within established therapeutic guidelines.

The medication is commonly used across conditions presenting with acute episodes, helping address symptom clusters related to physical discomfort that create noticeable physiological strain. It is generally applied in addressing acute pain of various origins, such as that associated with musculoskeletal injuries, including sprains and strains, as well as the intense, cyclical pain of primary dysmenorrhea (menstrual pain). This supportive relief contributes to improved comfort during periods of heightened symptoms, which may assist with maintaining functional stability.

Quick Fact: Role in Managing Pain, Inflammation, and Fever

Maxsulid is applied in addressing symptoms related to systemic imbalance, including elevated body temperature (fever). This symptomatic assistance helps address symptom clusters that may become intense or disruptive, is relevant for easing the overall burden of symptoms and may contribute to improved day-to-day comfort during symptomatic periods.

Regulatory References

  1. European Medicines Agency regulatory overview

Eligibility and Restrictions for Use

The official regulatory profile for Maxsulid (Nimesulide) establishes strict eligibility criteria, primarily due to risks related to liver function and other conditions. The medicine is primarily allowed for use in adults and adolescents from 12 years of age who are otherwise healthy.


Contraindicated Populations

Maxsulid must not be used in the following individuals or clinical states (absolute contraindications):

  • Age: Children under 12 years of age.
  • Organ Failure: Patients with any degree of hepatic impairment (liver failure), severe renal impairment (creatinine clearance < 30 ml/min), or severe heart failure.
  • GI Conditions: Those with active gastrointestinal ulceration, bleeding, or a history of recurrent ulcers related to prior NSAID use.
  • Hypersensitivity: Known hypersensitivity to Nimesulide or other NSAIDs (e.g., aspirin), or a history of hepatotoxic reactions to Nimesulide.
  • Reproductive Status: Women in the third trimester of pregnancy and those who are breastfeeding.

Restricted or Conditional Use

Usage requires additional caution or is not recommended in certain groups:

  • Older Adults (Geriatrics): Requires appropriate clinical monitoring.
  • Early Pregnancy: Not recommended in the first and second trimesters of pregnancy.
  • Specific Comorbidities: Use requires caution in patients with a history of gastrointestinal disorders (like Crohn's disease or ulcerative colitis) or mild to moderate renal/cardiac impairment.
  • Fertility: Not recommended for women attempting to conceive, as it may impair female fertility.

The overall regulatory structure defines eligibility by strictly excluding patients with pre-existing organ or bleeding risks.

What should I know about interactions with other medicines?

Maxsulid contains two active substances, nimesulide (a non-steroidal anti-inflammatory drug or NSAID) and pridinol (a centrally acting muscle relaxant). Both components can interact with other medicines, potentially increasing the risk of side effects or altering the effects of the concurrent medication. Always inform your doctor or pharmacist of all prescription and non-prescription medicines, vitamins, and herbal supplements you are taking.

Maxsulid-Containing NSAID (Nimesulide) Interactions

Category of Interacting Drug Potential Effect and Risk
Anticoagulants (e.g., Warfarin) and Antiplatelets (e.g., Aspirin) Increased risk of bleeding or hemorrhage, particularly in the gastrointestinal tract.
Other NSAIDs (including Cox-2 inhibitors) Increased risk of severe side effects, especially gastrointestinal bleeding and kidney impairment. Should be avoided.
Diuretics (e.g., Furosemide) and ACE inhibitors/ARBs Reduced effectiveness of blood pressure/heart failure drugs; increased risk of kidney impairment.
Lithium Increased plasma lithium levels, leading to an increased risk of lithium toxicity.
Methotrexate and Cyclosporine Increased toxicity of these drugs, especially in the kidneys (nephrotoxicity).

Pridinol Interactions

Pridinol may increase the risk or severity of Central Nervous System (CNS) depression when combined with other agents that also cause CNS depressant effects. This includes, but is not limited to, certain tranquilizers, sedatives, hypnotics, opioid pain relievers, and alcohol. This interaction can lead to increased drowsiness, dizziness, and difficulty concentrating, and may impair motor skills.

Mechanism of Action

Maxsulid's action is defined by a multi-modal pharmacodynamic mechanism centered on the selective modulation of inflammatory pathways and supporting systems.

Preferential Inhibition of the COX-2 Enzyme

The primary action of the active ingredient, Nimesulide, is its function as a preferential inhibitor of the Cyclooxygenase-2 (COX-2) enzyme. This binding substantially reduces the synthesis of pro-inflammatory prostaglandins ( PGE2) at sites of tissue distress. This molecular blockade modifies the early steps of the Arachidonic Acid cascade, directly limiting vasodilation and reducing nociceptor sensitization.

Modulation of Non-Prostaglandin Pathways and CNS Activity

Beyond its COX-2 effect, the drug influences auxiliary biological pathways by inhibiting enzymes like Myeloperoxidase (MPO), which reduces the creation of damaging oxidative free radicals, and by limiting the release of Matrix Metalloproteinases (MMPs) that degrade tissue. Furthermore, the molecule modulates central nervous system (CNS) signaling involved in the processing of discomfort and fever. These supplementary actions broaden the physiological modulation of the inflammatory state and contribute to the modulation of the hypothalamic temperature set-point.

Dosage and Administration Information

Instruction Map: How to use Maxsulid — Administration Guidelines

Maxsulid administration, containing the active ingredient Nimesulide, is governed by parameters that define its use as a systemic agent. The route for this preparation is oral administration.

Administration Scope

The standard regimen for adult use establishes a dose of 100 mg per intake, to be taken twice daily, which results in a maximum allowed daily intake of 200 mg. This dosing schedule is contextually linked to meals, as the medicine is directed to be taken after a meal. Forms such as granules require dissolution or preparation prior to ingestion.

A critical constraint in the overall usage protocol is the required time limitation, which stipulates that the total duration of the treatment course must not exceed 15 days.

Population-Specific Use

Administration rules are defined for specific patient groups. For both older adults and adolescents (12 to 18 years), no dosage adjustment from the standard adult regimen is required. Similarly, for patients with mild to moderate renal impairment (creatinine clearance 30-80 ml/min), the standard dosage is generally maintained.

Use-Context Constraints

Nimesulide is constrained to be used only as a second-line treatment. This requirement reinforces the principle of using the minimum effective dose for the shortest possible duration necessary to control symptoms.

Resulting Procedural Structure

The protocol dictates the use of the 100 mg dose taken twice daily, always ingested after a meal. This procedural structure ensures the medicine is used in compliance with the time-limited and minimum-dose principles.

Recent Clinical Evidence

Research evidence / Overview of Studies for Maxsulid

The Landscape of Clinical Research for Maxsulid

Maxsulid, which contains the active ingredient Nimesulide, has been the subject of a large volume of studies, including over two hundred clinical trials and numerous scientific reviews and meta-analyses. The overall purpose of this research was to examine outcomes related to systemic or functional imbalance, particularly those linked to inflammatory states. The evidence available contributes to the broader evidence landscape for short-term symptom management.

The studies primarily used Randomized Controlled Trials (RCTs), where researchers explored short-term symptom changes by comparing the study population to a placebo (an inactive substance) or to other pain relievers. The findings describe patterns observed in the studies that were then reviewed by regulatory bodies to contextualize the data related to episodic or acute changes in patient condition.


Evidence for Use in Acute Pain Relief

Research explored outcomes related to physical discomfort in conditions associated with acute or disruptive episodes, such as those related to musculoskeletal injuries and dental procedures. Short-term RCTs were applied in studies examining patient-reported experiences of pain and symptom intensity or variability.

Studies conducted during periods of increased symptom activity examined pain intensity scores when the study population was compared to an inactive treatment group. Findings also indicate data show patterns related to the speed of activity related to physical discomfort; some studies observed time intervals related to symptom change that were shorter than those reported for certain other specific NSAIDs. Evidence derived from settings with varying symptom burdens also suggests that research explored outcomes related to comparability with data reported for other common pain relievers.

What remains unclear is the medicine's application in conditions marked by chronic functional limitations. Follow-up durations were limited to short periods, and long-term effects are not fully established because official regulatory limitations require short-term use only.

Frequently Asked Questions (FAQ)

Common questions about Maxsulid (FAQ)


Q: Is Maxsulid the same kind of drug as common over-the-counter pain relievers?

Official product information confirms that the active ingredient in Maxsulid is a Non-Steroidal Anti-Inflammatory Drug (NSAID). Unlike some common over-the-counter NSAIDs, it is specifically classified as a preferential COX-2 enzyme inhibitor, belonging to the sulfonanilide chemical class.

Q: How quickly does Maxsulid usually start working?

Studies and official information indicate that Maxsulid has a relatively rapid onset of action. In some clinical examinations, pain relief effects were observed within 15 minutes. The maximum concentration in the body is generally reached between one to three hours after taking the medicine.

Q: How long does the effect of a Maxsulid dose last in the body?

Regulatory data describes how the medicine is processed by the body. The half-life of the active substance in the plasma, which indicates the time it takes for half of the drug to be eliminated, is generally between two to five hours for the parent drug and up to nine hours for its active metabolite.

Q: What happens if I miss a scheduled dose of Maxsulid?

Regulatory patient information suggests taking a missed dose as soon as it is remembered, unless the time is near for the next scheduled dose. Regulatory guidance strictly advises that the dose should never be doubled to compensate for a missed dose.

Q: Why is Maxsulid sometimes prescribed instead of other pain medications?

According to official product guidelines, Maxsulid is designated as a second-line treatment. This means regulatory authorities require it to be considered only after other initial medicines or treatment strategies have not been successful. It is always intended for the shortest possible duration of use.

Q: How often do serious side effects from Maxsulid occur based on research?

Studies indicate that the most severe documented risk, which is liver injury (hepatotoxicity), occurs rarely. One authoritative estimate suggests the frequency of this rare event is approximately 1 case in every 50,000 patients treated.

Q: Do the side effects of Maxsulid tend to go away over time?

Official safety literature indicates that common side effects are usually transient (temporary). Furthermore, most reported cases of drug-induced liver injury typically resolve within a few days once use of the medicine is discontinued.

Q: Can Maxsulid cause changes in sleep patterns or insomnia?

Official adverse drug reaction reports indicate that changes in sleep patterns, specifically insomnia (difficulty sleeping), are listed as a common reported side effect of Maxsulid.

Q: What are the signs of a severe allergic reaction to Maxsulid?

Regulatory documents list several possible signs of a severe allergic reaction. These may include difficulty breathing, a generalized skin rash, itching, and swelling of the face, tongue, or throat (known as angioedema or anaphylactic shock). Rarer, severe skin reactions like Stevens-Johnson syndrome have also been reported.

Q: Is Maxsulid known to cause drowsiness or impair driving ability?

Official safety information states that Maxsulid can cause side effects such as drowsiness (somnolence), dizziness, and visual problems. Due to these potential effects, official safety information notes that caution may be necessary when driving or operating heavy machinery.

Q: Does Maxsulid interact with common cold or allergy medications?

Maxsulid is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Product information highlights that concurrent use with other NSAIDs, which are sometimes found in common cold or pain relief products, may be contraindicated due to an increased risk of severe side effects.

Q: Why is Maxsulid generally not recommended for older adults?

Official data shows that advanced age does not significantly alter how the body processes the medicine. However, increased clinical monitoring is generally required for older adults. This caution is a standard measure associated with the use of most medicines in the NSAID class in this population.

Q: Can a person with high blood pressure safely use Maxsulid?

Official safety reports state that Maxsulid can potentially cause an increase in blood pressure, known as hypertension. Furthermore, it may reduce the intended effectiveness of certain blood pressure medicines. Severe heart failure is listed as a contraindication for its use.

Q: What is the definition of a 'contraindication' for Maxsulid?

The term 'contraindication' refers to a known condition, disease, or factor that serves as a reason to withhold Maxsulid treatment due to the high risk of harm to the patient. If a condition is listed as a contraindication, the drug must not be used.

Q: Has Maxsulid received any special warnings, such as a 'Black Box Warning,' from regulatory bodies?

Official regulatory history shows that in some jurisdictions, Maxsulid has been subject to a 'Box Warning' mandate by regulatory bodies. This is a severe regulatory measure imposed due to documented concerns about the potential risk of severe liver toxicity associated with the medicine.

Q: Is Maxsulid available in all countries under the same name?

No. The drug's active ingredient, Nimesulide, is not approved for use in all countries. Its use is prohibited or remains unapproved in several major jurisdictions, including the United States, the United Kingdom, and Canada, based on regulatory evaluations of its safety profile.

Q: What is the difference between Maxsulid tablets and capsules, if both exist?

Maxsulid is typically available as tablets and as granules for oral suspension. Pharmacokinetic studies suggest there can be a difference in how quickly the body absorbs the medicine, with the granular/suspension form sometimes achieving its maximum concentration faster than the tablet form.

Q: What is the risk profile of Maxsulid compared to non-prescription anti-inflammatory medicines?

Regulatory bodies have assessed that the overall benefit and risk profile of Maxsulid is generally consistent with that of other prescribed NSAIDs. This assessment is conditional on its strict use limitations, specifically the maximum treatment duration of 15 days, which is imposed due to the risk of liver damage.

Q: Why is a prescription required for Maxsulid?

Maxsulid is restricted to prescription-only status because regulatory guidelines impose strict limitations on its use. These limitations include its second-line status, the maximum 15-day treatment duration, and the need for clinical monitoring due to the established risk of liver injury.

Q: Can Maxsulid be crushed or split into smaller pieces?

Official patient instructions state that Maxsulid tablets must be swallowed whole and are not designed to be crushed, broken, or chewed. If the medicine is in the form of a dispersible tablet or granules, specific instructions for dissolution or preparation must be followed before ingestion.

Q: Is it normal to feel a tingling sensation after starting Maxsulid?

Yes, according to the official adverse reaction reports, paraesthesia (an abnormal sensation such as tingling) is listed as an uncommon reported side effect of Maxsulid.

Q: Why do some patient forums describe Maxsulid as a 'stronger' option?'

The active substance has demonstrated a fast rate of oral absorption in studies. Clinical evidence shows a relatively rapid onset of action, with effects observed in some studies within 15 minutes of intake. This rapid onset may contribute to the common perception of the medicine having a potent effect.

Q: Can Maxsulid cause sensitivity to sunlight?

Official adverse drug reaction reports list photosensitivity as a rare side effect. Photosensitivity is an increased sensitivity to light that can result in an unusually severe reaction (such as a rash or intense sunburn) to sun exposure.

How should Maxsulid be stored and disposed of?

How to Store and Dispose of Maxsulid

The storage and disposal of Maxsulid (Nimesulide) must strictly adhere to regulatory requirements to maintain product stability and ensure safety.


Official Storage Requirements

Maxsulid must be stored at room temperature, typically defined as 20 C to 25 C (68 F to 77 F), and away from excess heat. The medicine must be kept in its original, tightly closed container to protect it from moisture and light.

Crucially, Maxsulid must be stored out of the sight and reach of children (P102) to prevent accidental ingestion.


Official Disposal Instructions

Unused or expired Maxsulid must not be disposed of in household waste or flushed down drains. Disposal must be in accordance with local, regional, and national regulations (P501). Patients are typically directed to take the product to an approved pharmaceutical waste collection point or pharmacy for proper handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Maxsulid found in:

A-Z Index: